Evidence map›Paper›PMID 33849246›Full record

ArticlePsychiatry investigation2021

The Burden of Agoraphobia in Worsening Quality of Life in a Community Survey in Italy.

Antonio Preti, Martina Piras, Giulia Cossu, Elisa Pintus, Mirra Pintus, Goce Kalcev, Federico Cabras, Maria Francesca Moro, Ferdinando Romano, Matteo Balestrieri and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatry investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 3 countries.

Antonio PretiDepartment of Neuroscience, University of Turin, Torino, Italy.
Martina PirasPhD Programme Innovation Sciences and Technologies, University of Cagliari, Cagliari, Italy.
Giulia CossuDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Elisa PintusDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Mirra PintusDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Goce KalcevPhD Programme Innovation Sciences and Technologies, University of Cagliari, Cagliari, Italy.
Federico CabrasDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Maria Francesca MoroMailman School of Public Health, Columbia University, New York, USA.
Ferdinando RomanoUniversity of Roma La Sapienza, Roma, Italy.
Matteo BalestrieriDAME, University of Udine, Udine, Italy.
Filippo CaraciDepartment of Drug Sciences, University of Catania, Catania, Italy.
Liliana Dell'OssoUniversity of Pisa, Pisa, Italy.
Guido Di SciascioDepartment of Mental Health, ASL Bari, Italy.
Filippo DragoDepartment of Drug Sciences, University of Catania, Catania, Italy.
Maria Carolina HardoyAzienda Ospedaliera Brotzu, Cagliari, Italy.
Rita RonconeUniversity of L'Aquila, L'Aquila, Italy.
Carlo FaravelliUniversity of Florence, Florence, Italy.
Mario MusuDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Gabriele FincoDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Antonio Egidio NardiFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Mauro Giovanni CartaDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
University of Cagliari · ITUniversity of Catania · ITAzienda Ospedaliera G. Brotzu · ITAzienda Sanitaria Locale Roma 3 · ITColumbia University · USSapienza University of Rome · ITUniversidade Federal do Rio de Janeiro · BRUniversity of Florence · ITUniversity of L'Aquila · ITUniversity of Pisa · ITUniversity of Turin · ITUniversity of Udine · IT

Funding

Agenzia Italiana del Farmaco, Ministero della Salute FARM54S73S
6 · The paper itself

Abstract

objectiveCurrent nosology redefined agoraphobia as an autonomous diagnosis distinct from panic disorder. We investigated the lifetime prevalence of agoraphobia, its association with other mental disorders, and its impact on the health-related quality of life (HR-QoL).

methodsCommunity survey in 2,338 randomly selected adult subjects. Participants were interviewed with the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), administered by clinicians. The diagnoses were based on the ICD-10 criteria. The Short-Form Health Survey (SF-12) was used to quantify HR-QoL.

resultsIn the sample, 35 subjects met the criteria for agoraphobia (1.5%), with greater prevalence among women (2.0%) than men (0.9%): odds ratio (OR) 2.23; 95% CI: 1.0-5-2. Agoraphobia was more often seen among those with (n=26; 1.1%) than without (n=9; 0.4%) panic disorder: OR=8.3; 2.9-24.4. Co-morbidity with other mental disorders was substantial. The mean score of SF-12 in people with agoraphobia was 35.2±7.8, with similar levels of HR-QoL in people with (35.3±7.9) or without (34.8±7.3) panic disorder: ANOVA: F(1;33)=0.0; p=1.00.

conclusionOne out of seventy people may suffer from agoraphobia in their lifetime. The attributable burden in terms of HR-QoL is substantial and comparable to the one observed for chronic mental disorders such as major depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Indexed as

AgoraphobiaCommunity surveyEpidemiologyMajor depressive disorderPanic disorderQuality of life

Identifiers

PMID33849246
PMCPMC8103017
OpenAlexW3154837501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.